Boehringer strikes €307M col­lab­o­ra­tion deal with Mi­NA; Tri­ci­da banks $57.5M ven­ture round for PhI­II

→ Boehringer In­gel­heim and Mi­NA Ther­a­peu­tics will col­lab­o­rate on new drugs for fi­brot­ic liv­er dis­eases like NASH. Mi­NA’s been work­ing on a small ac­ti­vat­ing RNA plat­form, and now is in line for up to €307 mil­lion in mile­stones.

→ South San Fran­cis­co-based Tri­ci­da has raised $57.5 mil­lion to com­plete an on­go­ing Phase III study of its lead drug. The mon­ey is ear­marked for TRC101, an ex­per­i­men­tal drug for chron­ic meta­bol­ic aci­do­sis in pa­tients with chron­ic kid­ney dis­ease. Welling­ton Man­age­ment Com­pa­ny LLP, Ven­rock Health­care Cap­i­tal Part­ners and Cor­morant As­set Man­age­ment joined ex­ist­ing in­vestors Or­biMed, Lon­gi­tude Cap­i­tal, Sib­ling Cap­i­tal Ven­tures, Limu­lus Ven­ture Part­ners and Vi­vo Cap­i­tal in the round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER